Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genetic Risk-Based Atrial Fibrillation Screening

NCT04932798 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.

NCT NCT04932798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04932798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genetic Risk-Based Atrial Fibrillation Screening
Lead sponsor
Montreal Heart Institute
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2021
Completion date
January 10, 2026
Enrollment
726 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, genetic predisposition